ARPA-H Funds Biotechs Developing Custom RNA Therapies
Source Summary
The Advanced Research Projects Agency for Health (ARPA-H) is funding biotechnology companies working on custom RNA therapies. The report also covers Roche's licensing of a tri-specific antibody and notes that new Trump administration deals may conflict with its own policy objectives.
Why it matters
ARPA-H funding for custom RNA therapies represents government investment in advancing precision medicine technologies with potential therapeutic applications.
